Metabolic and cardiovascular effects of TX-001HR in menopausal women with vasomotor symptoms

References

• Blumel JE, Chedraui P, Baron G. A large multinational study of vasomotor symptom prevalence, duration, and impact on quality of life in middle-aged women. Menopause 2011;18:778–85
   PubMed Web of Science ®Google Scholar
• Hunter MS, Gentry-Maharaj A, Ryan A, et al. Prevalence, frequency and problem rating of hot flushes persist in older postmenopausal women: impact of age, body mass index, hysterectomy, hormone therapy use, lifestyle and mood in a cross-sectional cohort study of 10,418 British women aged 54–65. BJOG 2012;119:40–50
   PubMed Web of Science ®Google Scholar
• Duffy OK, Iversen L, Hannaford P. The impact and management of symptoms experienced at midlife: a community-based study of women in northeast Scotland. BJOG 2012;119:554–64
   PubMed Web of Science ®Google Scholar
• Whiteley J, Wagner JS, Bushmakin A, Kopenhafer L, Dibonaventura M, Racketa J. Impact of the severity of vasomotor symptoms on health status, resource use, and productivity. Menopause 2013;20:518–24
   PubMed Web of Science ®Google Scholar
• Blumel JE, Cano A, Mezones-Holguin E, et al. A multinational study of sleep disorders during female mid-life. Maturitas 2012;72:359–66
   PubMed Web of Science ®Google Scholar
• Kleinman NL, Rohrbacker NJ, Bushmakin AG, Whiteley J, Lynch WD, Shah SN. Direct and indirect costs of women diagnosed with menopause symptoms. J Occup Environ Med 2013;55:465–70
   PubMed Web of Science ®Google Scholar
• The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of the North American Menopause Society. Menopause 2017;24:728–53
   PubMed Web of Science ®Google Scholar
• Henderson VW, Lobo RA. Hormone therapy and the risk of stroke: perspectives 10 years after the Women's Health Initiative trials. Climacteric 2012;15:229–34
   PubMed Web of Science ®Google Scholar
• Renoux C, Dell'Aniello S, Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: a population-based study. J Thromb Haemost 2010;8:979–86
   PubMed Web of Science ®Google Scholar
• Hale GE, Shufelt CL. Hormone therapy in menopause: an update on cardiovascular disease considerations. Trends Cardiovasc Med 2015;25:540–9
   PubMed Web of Science ®Google Scholar
• Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics–2015 update: a report from the American Heart Association. Circulation 2015;131:e29–322
   PubMed Web of Science ®Google Scholar
• Lobo RA, Pickar JH, Stevenson JC, Mack WJ, Hodis HN. Back to the future: hormone replacement therapy as part of a prevention strategy for women at the onset of menopause. Atherosclerosis 2016;254:282–304
   PubMed Web of Science ®Google Scholar
• Lobo RA, Bush T, Carr BR, Pickar JH. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. Fertil Steril 2001;76:13–24
   PubMed Web of Science ®Google Scholar
• Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA 1995;273:199–208
   PubMed Web of Science ®Google Scholar
• Scarabin PY, Hemker HC, Clement C, Soisson V, Alhenc-Gelas M. Increased thrombin generation among postmenopausal women using hormone therapy: importance of the route of estrogen administration and progestogens. Menopause 2011;18:873–9
   PubMed Web of Science ®Google Scholar
• Terauchi M, Honjo H, Mizunuma H, Aso T. Effects of oral estradiol and levonorgestrel on cardiovascular risk markers in postmenopausal women. Arch Gynecol Obstet 2012;285:1647–56
   PubMed Web of Science ®Google Scholar
• Canonico M. Hormone therapy and hemostasis among postmenopausal women: a review. Menopause 2014;21:753–62
   PubMed Web of Science ®Google Scholar
• Lobo RA. Clinical review 27: effects of hormonal replacement on lipids and lipoproteins in postmenopausal women. J Clin Endocrinol Metab 1991;73:925–30
   PubMed Web of Science ®Google Scholar
• Miller VT, Muesing RA, LaRosa JC, Stoy DB, Phillips EA, Stillman RJ. Effects of conjugated equine estrogen with and without three different progestogens on lipoproteins, high-density lipoprotein subfractions, and apolipoprotein A-I. Obstet Gynecol 1991;77:235–40
   PubMed Web of Science ®Google Scholar
• Hirvonen J, Blom M, Tuominen U, et al. Health-related quality of life in patients waiting for major joint replacement. A comparison between patients and population controls. Health Qual Life Outcomes 2006;4:3
   PubMed Web of Science ®Google Scholar
• Jiang Y, Tian W. The effects of progesterones on blood lipids in hormone replacement therapy. Lipids Health Dis 2017;16:219
   PubMed Web of Science ®Google Scholar
• Mirkin S. Evidence on the use of progesterone in menopausal hormone therapy. Climacteric 2018;21:346–54
   PubMed Web of Science ®Google Scholar
• Canonico M, Fournier A, Carcaillon L, et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. ATVB 2010;30:340–5
   Google Scholar
• Canonico M, Carcaillon L, Plu-Bureau G, et al. Postmenopausal hormone therapy and risk of stroke: impact of the route of estrogen administration and type of progestogen. Stroke 2016;47:1734–41
   PubMed Web of Science ®Google Scholar
• Lobo RA, Archer DF, Kagan R, et al. A 17β-estradiol-progesterone oral capsule for vasomotor symptoms in postmenopausal women: a randomized controlled trial. Obstet Gynecol 2018;132:161–70
   PubMed Web of Science ®Google Scholar
• Bijuva™ (Estradiol and Progesterone) Capsules, for Oral Use Prescribing Information. Boca Raton, FL: TherapeuticsMD; 2018
   Google Scholar
• Lobo RA, Liu J, Stanczyk FZ, et al. Estradiol and progesterone bioavailability for moderate to severe vasomotor symptom treatment and endometrial protection with the continuous-combined regimen of TX-001HR (oral estradiol and progesterone capsules). Menopause 2019;26:720
   PubMed Web of Science ®Google Scholar
• Harman SM, Black DM, Naftolin F, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women. Ann Intern Med 2014;161:249–60
   PubMed Web of Science ®Google Scholar
• Hodis HN, Mack WJ, Lobo RA, et al. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001;135:939–53
   PubMed Web of Science ®Google Scholar
• Prior JC, Elliott TG, Norman E, Stajic V, Hitchcock CL. Progesterone therapy, endothelial function and cardiovascular risk factors: a 3-month randomized, placebo-controlled trial in healthy early postmenopausal women. PLoS One 2014;9:e84698
   PubMed Web of Science ®Google Scholar
• Mikkola TS, Savolainen-Peltonen H, Venetkoski M, Ylikorkala O. New evidence for cardiac benefit of postmenopausal hormone therapy. Climacteric 2017;20:5–10
   PubMed Web of Science ®Google Scholar
• Reslan OM, Khalil RA. Vascular effects of estrogenic menopausal hormone therapy. Rev Recent Clin Trials 2012;7:47–70
   PubMedGoogle Scholar
• Mikkola TS, Tuomikoski P, Lyytinen H, et al. Estradiol-based postmenopausal hormone therapy and risk of cardiovascular and all-cause mortality. Menopause 2015;22:976–83
   PubMed Web of Science ®Google Scholar
• Lobo RA. Evaluation of cardiovascular event rates with hormone therapy in healthy, early postmenopausal women: results from 2 large clinical trials. Arch Intern Med 2004;164:482–4
   PubMed Web of Science ®Google Scholar
• Cushman M, Kuller LH, Prentice R, et al. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004;292:1573–80
   PubMed Web of Science ®Google Scholar
• Steinkellner AR, Denison SE, Eldridge SL, Lenzi LL, Chen W, Bowlin SJ. A decade of postmenopausal hormone therapy prescribing in the United States: long-term effects of the Women's Health Initiative. Menopause 2012;19:616–21
   PubMed Web of Science ®Google Scholar
• Gass ML, Stuenkel CA, Utian WH, et al. Use of compounded hormone therapy in the United States: report of the North American Menopause Society Survey. Menopause 2015;22:1276–84
   PubMed Web of Science ®Google Scholar
• Fishman JR, Flatt MA, Settersten RA Jr. Bioidentical hormones, menopausal women, and the lure of the ‘natural’ in U.S. anti-aging medicine. Soc Sci Med 2015;132:79–87
   PubMed Web of Science ®Google Scholar
• American College of Obstetricians and Gynecologists. Compounded bioidentical menopausal hormone therapy. Committee opinion no. 532. Obstet Gynecol 2012;120:411–15
   PubMedGoogle Scholar
• Manson JE, Kaunitz AM. Menopause management – getting clinical care back on track. N Engl J Med 2016;374:803–6
   PubMed Web of Science ®Google Scholar
• Pinkerton J, Santoro N. Compounded bioidentical hormone therapy: identifying use trends and knowledge gaps among US women. Menopause 2015;22:926–36
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Pickar JH. Update on medical and regulatory issues pertaining to compounded and FDA-approved drugs, including hormone therapy. Menopause 2016;23:215–23
   PubMed Web of Science ®Google Scholar
• Eden JA, Hacker NF, Fortune M. Three cases of endometrial cancer associated with ‘bioidentical’ hormone replacement therapy. Med J Aust 2007;187:244–5
   PubMed Web of Science ®Google Scholar
• Davis R, Batur P, Thacker HL. Risks and effectiveness of compounded bioidentical hormone therapy: a case series. J Womens Health (Larchmt) 2014;23:642–8
   PubMed Web of Science ®Google Scholar
• Dezman VL, Gersak MZ, Gersak K. Two cases of atypical endometrial hyperplasia associated with ‘bioidentical’ hormone replacement therapy: IGCS-0084 uterine cancer, including Sarcoma. Int J Gynecol Cancer 2015;25: Suppl 1:71
   PubMed Web of Science ®Google Scholar
• Stuenkel C, Manson J. Compounded bioidentical hormone therapy: does the regulatory double standard harm women?. JAMA Intern Med 2017;177:1719–20
   PubMed Web of Science ®Google Scholar
• Pickar JH, Bon C, Amadio JM, Mirkin S, Bernick B. Pharmacokinetics of the first combination 17beta-estradiol/progesterone capsule in clinical development for menopausal hormone therapy. Menopause 2015;22:1308–16
   PubMed Web of Science ®Google Scholar
• Constantine G, Revicki DA, Kagan R, Simon J, Graham S, Mirkin S. TX-001HR is associated with a clinically meaningful effect on vasomotor symptoms. Menopause 2017;24:1428
   Web of Science ®Google Scholar
• Simon JA, Kaunitz A, Kroll R, Graham S, Bernick B, Mirkin S. Oral 17β-estradiol-progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptoms. Menopause 2019;26:506–12
   PubMed Web of Science ®Google Scholar
• Kagan R, Constantine G, Kaunitz A, Gasper G, Bernick B, Mirkin S. TX-001HR improved the Medical Outcomes Study-Sleep (MOS-Sleep) questionnaire in menopausal women with vasomotor symptoms (S-17). Menopause 2017;24:1431
   Web of Science ®Google Scholar
• Sutton SS, Hardin JW, Bramley TJ, D'Souza AO, Bennett CL. Single- versus multiple-tablet HIV regimens: adherence and hospitalization risks. Am J Manag Care 2016;22:242–8
   PubMed Web of Science ®Google Scholar
• Coca A, Agabiti-Rosei E, Cifkova R, Manolis AJ, Redón J, Mancia G. The polypill in cardiovascular prevention: evidence, limitations and perspective – position paper of the European Society of Hypertension. J Hypertens 2017;35:1546–53
   PubMed Web of Science ®Google Scholar